These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2061 related items for PubMed ID: 12217812

  • 1. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA, Neelapu SS, Kwak LW, Biragyn A.
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [Abstract] [Full Text] [Related]

  • 2. Antitumor vaccination: where we stand.
    Bocchia M, Bronte V, Colombo MP, De Vincentiis A, Di Nicola M, Forni G, Lanata L, Lemoli RM, Massaia M, Rondelli D, Zanon P, Tura S.
    Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R.
    Cancer Res; 2002 Oct 15; 62(20):5845-52. PubMed ID: 12384547
    [Abstract] [Full Text] [Related]

  • 4. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen.
    Neelapu SS, Baskar S, Gause BL, Kobrin CB, Watson TM, Frye AR, Pennington R, Harvey L, Jaffe ES, Robb RJ, Popescu MC, Kwak LW.
    Clin Cancer Res; 2004 Dec 15; 10(24):8309-17. PubMed ID: 15623607
    [Abstract] [Full Text] [Related]

  • 5. Cell therapy: achievements and perspectives.
    Bordignon C, Carlo-Stella C, Colombo MP, De Vincentiis A, Lanata L, Lemoli RM, Locatelli F, Olivieri A, Rondelli D, Zanon P, Tura S.
    Haematologica; 1999 Dec 15; 84(12):1110-49. PubMed ID: 10586214
    [Abstract] [Full Text] [Related]

  • 6. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ, Guthmann MD, Gabri MR, Carnero AJ, Alonso DF, Fainboim L, Gomez DE.
    Oncol Rep; 2002 Dec 15; 9(2):267-76. PubMed ID: 11836591
    [Abstract] [Full Text] [Related]

  • 7. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
    Rinaldi M, Ria F, Parrella P, Signori E, Serra A, Ciafrè SA, Vespignani I, Lazzari M, Farace MG, Saglio G, Fazio VM.
    Cancer Res; 2001 Feb 15; 61(4):1555-62. PubMed ID: 11245465
    [Abstract] [Full Text] [Related]

  • 8. Ex vivo expansion of hematopoietic cells and their clinical use.
    Aglietta M, Bertolini F, Carlo-Stella C, De Vincentiis A, Lanata L, Lemoli RM, Olivieri A, Siena S, Zanon P, Tura S.
    Haematologica; 1998 Sep 15; 83(9):824-48. PubMed ID: 9825579
    [Abstract] [Full Text] [Related]

  • 9. The role of idiotype vaccines in the treatment of human B-cell malignancies.
    Bendandi M.
    Expert Rev Vaccines; 2004 Apr 15; 3(2):163-70. PubMed ID: 15056042
    [Abstract] [Full Text] [Related]

  • 10. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells.
    Fredriksen AB, Sandlie I, Bogen B.
    Mol Ther; 2006 Apr 15; 13(4):776-85. PubMed ID: 16414309
    [Abstract] [Full Text] [Related]

  • 11. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
    Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R.
    J Clin Oncol; 2004 Dec 01; 22(23):4717-24. PubMed ID: 15483014
    [Abstract] [Full Text] [Related]

  • 12. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
    Bertinetti C, Zirlik K, Heining-Mikesch K, Ihorst G, Dierbach H, Waller CF, Veelken H.
    Cancer Res; 2006 Apr 15; 66(8):4496-502. PubMed ID: 16618777
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS, Lee ST, Qin H, Cha SC, Woo AF, Kwak LW.
    Expert Rev Vaccines; 2006 Jun 15; 5(3):381-94. PubMed ID: 16827622
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help.
    Savelyeva N, King CA, Vitetta ES, Stevenson FK.
    Proc Natl Acad Sci U S A; 2005 Aug 02; 102(31):10987-92. PubMed ID: 16037207
    [Abstract] [Full Text] [Related]

  • 15. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.
    Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R.
    N Engl J Med; 1992 Oct 22; 327(17):1209-15. PubMed ID: 1406793
    [Abstract] [Full Text] [Related]

  • 16. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
    Wagner U, Köhler S, Prietl G, Giffels P, Schmidt-Nicolai S, Schlebusch H, Grünn U, Bender H, Biersack HJ, De Potter C, Krebs D, Wallwiener D.
    Zentralbl Gynakol; 1999 Oct 22; 121(4):190-5. PubMed ID: 10355096
    [Abstract] [Full Text] [Related]

  • 17. Idiotypic vaccination in B-cell malignancies.
    Bianchi A, Massaia M.
    Mol Med Today; 1997 Oct 22; 3(10):435-41. PubMed ID: 9358470
    [Abstract] [Full Text] [Related]

  • 18. A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines.
    Hakim I, Levy S, Levy R.
    J Immunol; 1996 Dec 15; 157(12):5503-11. PubMed ID: 8955200
    [Abstract] [Full Text] [Related]

  • 19. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.
    Int J Oncol; 2006 Apr 15; 28(4):947-53. PubMed ID: 16525645
    [Abstract] [Full Text] [Related]

  • 20. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity.
    Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O'Carroll K, Guarnieri F, Longo DL, Kwak LW.
    J Immunol; 1996 May 15; 156(10):3858-65. PubMed ID: 8621924
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 104.